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ABSTRACT
Objective: Identifying the predictors of hope in patients with breast cancer during 
chemotherapy treatment. Method: A prospective longitudinal study. The sample was 
composed of 122 women who responded to the instruments of hope, anxiety and 
depression, coping, fatigue, religiosity and self-esteem in the first and last cycle of 
chemotherapy. These variables were used in adjusting the logistic regression model that 
characterized multivariate statistics, allowing identification of predictor variables. Result: 
The increase of hope at the end of chemotherapy treatment was statistically significant 
(p = 0.012). The delay in undergoing treatment from the onset of breast cancer symptoms, 
Karnofsky Performance Status, depression, self-esteem and pain were characterized as 
factors being associated to hope by univariate analysis. Among the variables analyzed, 
pain was the only predicting factor of hope. Conclusion: Pain was the predicting factor 
in this sample. Hope increased during treatment and revealed the following associated 
factors: Karnofsky Performance Status, delay in starting the treatment, depression, self-
esteem and pain. This study brought forth a multidisciplinary contribution, allowing for 
understanding the factors that can influence hope and presenting support to nursing care. 
The data evidenced conditions of improvement or worsening of hope, which requires 
interdisciplinary attention in Oncology.
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INTRODUCTION
The diagnosis of cancer arouses innumerable feelings and 
emotions, among them, hope. This feeling can be seen as a 
resource that helps patients in coping with psychological 
suffering associated to the disease(1-3).
In the medical field, all definitions of hope involve some-
thing that is desired in the future, and when it is associated 
to the present it can have a positive influence on well-being 
or, at least, reflect in a positive state(2).
Having hope is essential after a cancer diagnosis is dis-
closed, since the news can cause suffering and is usually 
received as a threat. The patient often believes that the diag-
nosis of cancer is a death sentence, probably resulting in a 
profound loss of hope, leading to deleterious consequences 
to their prognosis(4). Maintaining hope enables incurable 
cancer patients to accept treatment or clinical research, even 
if there are few benefits(2).
The study of this construct has aroused interest, as it 
seems to be directly related to the success of cancer treat-
ments and management of signs and symptoms(5-6). Hope 
presents some strategies that facilitate the daily practice of 
nursing. It is made feasible by human principles which are 
the basis of care, by the use of knowledge put into practice, 
by interpersonal relationships, and how health professionals 
handle the environment and care organization(7).
Nurses are an important source of hope for people who 
are vulnerable and ill, as they are in constant contact with 
those who are suffering(7). This is particularly true for onco-
logic patients who, due to their long stay in the hospital 
environment and the repeated returns established by the 
treatment protocols, maintain close contact with nurses, in 
addition to the affective bond created.
Some variables frequently associated to hope have been 
identified by scientific studies, and understanding them 
can influence the quality of care. Regarding this, there is 
religiosity, a factor that is usually evaluated in the spiritual 
domain of the instruments that evaluate quality of life as 
being possibly weakened by a cancer diagnosis, and may lead 
the patient to contemplate their own mortality and often 
poses unique challenges to their beliefs(4,8).
Other associated variables may include:
Fatigue: The cancer patient often presents a fatigue 
symptom, whether it is due to illness or to treatment(2,9).
Karnofsky Performance Status (KPS): The functional clini-
cal condition of the cancer patient is usually assessed by assess-
ment scales, such as KPS, being necessary for clinical decision-
making. It was found that low KPS scores, which indicate low 
functionality, are related to a lower index of hope(1).
Coping: Literature associates hope as an important 
resource and coping mechanism(1).
Anxiety and depression: Hope and optimism are nega-
tively correlated to anxiety and depression(10-11). The higher 
the hope scores, the lower the possibility of the patient pre-
senting a score of depression(5-6).
Hope and self-esteem: self-esteem in patients with breast 
cancer, from the discovery of the disease and during treat-
ment is subject to change, constituting an important object 
of study(5,12). Despite the physical and psychological changes 
suffered by these patients, they present high self-esteem(12).
It is important to identify the factors that influence 
hope. Anxiety, depression, fatigue and pain negatively affect 
the hope(11).
The present study investigates which other variables can 
be associated to or be predictors of hope in patients with 
breast cancer during chemotherapy treatment. The inter-
est in the topic as well as the small number of studies that 
investigate such factors have fostered the development of 
the present study, aiming to identify predictors of hope in 
patients with breast cancer during chemotherapy treatment.
METHOD
This is a prospective longitudinal study conducted at 
a public hospital, which is a reference center for Women’s 
Health, in the city of São Paulo, SP, Brazil.
The inclusion criteria for the sample composition were: 
patients with breast cancer at clinical stage I, II and III(13); 
being more than 18 years of age; aware of their diagnosis; 
in the first chemotherapy treatment; and able to read and 
respond to the questionnaires.
Patients with metastatic disease and those who did not 
complete treatment at the chemotherapy outpatient center 
referenced above were excluded from the study.
The study participants were previously selected from 
appointments and medical records in the Chemotherapy 
Outpatient Clinic.
The patients were approached by the principal investi-
gator in the first cycle of chemotherapy and the objectives 
and benefits of the study in question were clarified, allowing 
them to express their desire to participate. Those interested 
in participating signed the Free and Informed Consent 
Form. They were guided regarding the need to respond to 
all the questionnaires necessary to achieve the objectives 
of the study in the proposed first cycle of chemotherapy, 
characterizing zero time (T0). The same questionnaires were 
completed again in the last cycle of chemotherapy, which 
characterized the final time (T1).
Data collection was carried out from March 2011 
to March 2012.
An instrument created by the researchers of this study 
was used to obtain sociodemographic data (age, gender, 
marital status, education, religion, current occupation and 
family income) and clinical data (onset of symptoms, date 
of diagnosis, staging, current treatment, chemotherapy 
protocol, previous treatments, comorbidities and pain). 
Information regarding disease stage, other treatments and 
chemotherapy protocol were obtained through active medi-
cal record consultation.
The dependent variable in this study was the evaluation 
of hope, and was performed using the Herth Hope Index 
(HHI), culturally adapted and validated for the Portuguese 
language. This index makes it possible to measure the hope 
construct in a final score ranging from 12 to 48. The index 
has 12 easy-to-understand items(5). There is no cut-off point, 
resulting in a high or low score of hope and it has been 
validated in several countries(3).
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Karnofsky Performance Status (KPS) was used to evaluate 
the patients’ health status. The Karnofsky scale is composed of 
sentences that portray the functional capacity of an individual, 
and these are graded from 100% to 0%, where 100% repre-
sents an individual with no evidence of disease and 0% is a 
deceased person. There are no cut-off points, and higher scores 
indicate better functionality. It is a widely-used instrument 
in international and national cancer studies and clinics(14).
The Numerical Pain Scale was also used since it allows 
patients to characterize pain intensity using a numerical 
value from 0 to 10 (0 = absence of pain and 10 = worst pain 
imaginable), where 0 – without pain; 1 – mild pain (1-4); 
2 – moderate pain (5-7); 3 – severe pain (8-10)(15).
The Jalowiec Coping Scale had the objective of identify-
ing individual characteristics of strategies for coping with 
stressors. It consists of 60 statements divided into eight 
styles of coping, namely: confrontational, evasive, optimis-
tic, fatalistic, emotive, palliative, supportive, and self-reliant. 
The Jalowiec Coping Scale was validated for the Brazilian 
older adult population with cognitive impairment, observing 
good reliability. For the final score, the highest relative score 
is found, which represents the predominant coping style(16).
The Hospital Anxiety and Depression Scale (HADS) 
contains 14 multiple-choice questions and it has also been 
validated for the Portuguese language. It consists of two 
subscales for anxiety and depression, with seven items each. 
The overall score for each subscale ranges from 0 to 21. The 
recommended cut-off points for both subscales are: HAD 
– anxiety: no anxiety from 0 to 8, having anxiety ≥ 9; HAD 
– depression: no depression from 0 to 8, having depression 
≥ 9. It is a scale of easy application and understanding(17).
The Rosenberg Self-Esteem Scale (RSES) assessed the 
self-esteem of patients in this study. It is a scale composed of 
10 affirmations with a score of 0 to 3. The higher the score, 
the lower the self-esteem. The Portuguese version of this 
scale presented good reproducibility and validity indexes 
with patients who were to undergo plastic surgery(18).
The Duke Religion Index (DUREL) has five items that 
capture three of the dimensions of religiosity that are most 
related to health outcomes: Organizational religiosity (OR) 
– first question; Non-organizational religion (NOR) – sec-
ond question; Intrinsic Religiosity (IR) – grouping of the 
last three questions. The version adapted for Portuguese is 
available for use, however the authors suggest that validity 
and reliability studies of this version are carried out in the 
Brazilian population. In order to obtain the final score, the 
number corresponding to the response is associated to the 
result in that dimension, but with an inverted score, meaning 
that higher scores represent less religiosity(19).
An assessment of fatigue was performed using the 
Fatigue Pictogram, an instrument validated for Brazilian 
culture. The Pictogram is a scale composed of two ques-
tions graded in five subtitled illustrations that evaluate the 
intensity and impact of fatigue. There is no cut-off point for 
diagnosis or classification of fatigue intensity. Each item was 
evaluated separately for the psychometric properties test(20).
The predictor factor was revealed through multiple 
regression which used independent variables to predict 
the dependent variable of hope. Regression analysis deter-
mines values for each independent variable. The weighting 
of each independent variable reveals its contribution for 
global prediction and assists in understanding each variable 
in the prediction(21).
The project was approved by the Research Ethics 
Committee of the Universidade de São Paulo Escola de 
Enfermagem, CEP EEUSP (Process nº 976/2010), and 
of the Reference Center for Women’s Health (Protocol 
nº 034/10).
RESULTS
The convenience sample from the chemotherapy schedule 
was initially composed of 165 individuals who met the inclu-
sion criteria. The subjects were all interviewed and responded 
to the intended instruments at the first chemotherapy session. 
One hundred and twenty-two (122) women concluded the 
study, being those who responded again to the questionnaires 
at the end of the chemotherapy treatment. Losses occurred 
due to metastatic disease in 18 (11%) of the subjects as con-
firmed in medical records after the first interview, 2 (1%) due 
to deaths, and 23 (14%) due to changes in schedules.
The patients had a mean age of 50 years (SD = 10.6), 
most of them were married and Catholic. Study participants 
had median schooling of 8.5 years. Regarding monthly family 
income, the sample obtained a median of R$1,200.00 (BRL).
The onset of breast cancer symptoms showed a median 
of 8 months, with a minimum of 3 months and a maxi-
mum of 46 months. The time between the diagnosis and the 
beginning of the treatment showed a median of 4 months, a 
minimum of 1 month and maximum of 13 months.
The main chemotherapeutic protocols used in this 
sample were: AC/T-Adriamycin and Cyclophosphamide/
Taxol® (39.5%) adjuvant post-operative breast surgery, four 
cycles of Adriamycin (60 mg/m2) and Cyclophosphamide 
(600 mg/m2), followed by four cycles of Taxol® (175 mg/m2) 
every 21 days; FAC – Fluorouracil (5-FU), Adriamycin and 
Cyclophosphamide (16.5%), six cycles of Fluorouracil (5-FU) 
(500 mg/m2), Adriamycin (50 mg/m2) and Cyclophosphamide 
(600 mg/m2) every 21 days; and the Multicentric Research 
Protocol (12%), in which Docetaxel (75 mg/m2), Adriamycin 
(50 mg/m2) and Cyclophosphamide (500 mg/m2) were used 
for six cycles every 21 days. The mean duration of chemo-
therapy treatment between T0 and T1 was 4.2 months.
Surgical treatment (mastectomy or quadrantectomy) was 
performed in 77 patients (63%) prior to chemotherapy.
The variation of the scores obtained by applying the 
Herth Hope Index (HHI) in the studied sample obtained 
the following values: median of 43 at T0, and median of 45 
at T1. This increase at the end of the chemotherapy treat-
ment was statistically significant (p = 0.012).
As the Herth Hope Index does not have a cut-off point, 
it was necessary to divide the sample into two groups; one 
for which the hope score during treatment was maintained 
or increased, and another in which it decreased. There was a 
decrease in the HHI score in 35% of the sample. All analyzes 
to identify predictors were made considering the catego-
rized hope variation (decreased or maintained/increased) 
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at moments T0 and T1. These analyzes characterize the 
univariate statistics, which enabled studying of variables 
associated to hope.
The delay in starting treatment for patients since the 
onset of breast cancer symptoms showed a median time of 8 
months. The patients who took longer to start chemotherapy 
showed a significant decrease in hope scores over the same 
period (p = 0.013). Univariate analysis characterizes this 
variable as a factor associated to hope.
The group with decreased hope scores presented lower 
KPS values at time T1. This decrease was statistically sig-
nificant (p = 0.02). Univariate analysis characterizes this 
variable as a factor associated to hope.
An assessment of anxiety and depression was carried out 
and associated to the variation of hope between T0 and T1. 
The association is shown in Table 1.
Table 1 – Association between the variation of Hope, Anxiety and 
Depression at time zero and final time – São Paulo, SP, Brazil, 2012.
Variable HHI Score (T1-T0) Median
Interquartile 
range (1st and 
3rd quartile)
p
HADS Score 
A* T0
Maintained/
Increased 6 3 10 0.721
Decreased 6 4 8
HADS Score 
A T1
Maintained/
Increased 4 2 7 0.087
Decreased 5 3 9
HADS Score 
D† T0
Maintained/
Increased 4 2 6 0.645
Decreased 5 3 6
HADS Score 
D T1
Maintained/
Increased 3 1 5 0.004
Decreased 5 3 8
*Score A: Anxiety Score, † Score D: Depression Score.
The group whose hope decreased during the treat-
ment presented a significant increase in depression scores 
(p = 0.004). Univariate analysis characterizes this variable 
as a factor associated to hope.
The results of the association between variation of 
hope during treatment and self-esteem are demonstrated 
in Table 2.
Table 2 – Association between variation of Hope and Self-esteem 
at time zero and final time – São Paulo, SP, Brazil, 2012.
Variable HHI Score (T1-T0) Median
Interquartile 
range (1st and 3rd 
quartile)
p
RSES* 
Score T0
Maintained/
Increased 8 3 11 0.060
Decreased 6 2 9
RSES 
Score T1
Maintained/
Increased 3 2 7 0.001
Decreased 7 3 10
*RSES: Rosenberg Self-Esteem Scale.
These results demonstrate that the group that had 
decreased hope between T0 and T1 had higher self-esteem 
scores at T1 (p = 0.001). The RSES score is inverted, meaning 
that the patients who had decreased hope had lower self-
esteem. Univariate analysis characterizes this variable as a 
factor associated to hope.
The investigation of pain at the beginning and at the 
end of treatment associated to the variation of hope is rep-
resented in Table 3.
Table 3 – Association between the variation of Hope and Pain at 
time zero and final time – São Paulo, SP, Brazil, 2012.
Variable HHI Score (T1-T0) Median
Interquartile 
range (1st and 3rd 
quartile)
p
Pain T0
Maintained/
Increased 0 0 5 0.034
Decreased 4 0 7
Pain T1
Maintained/
Increased 0 0 3 0.641
Decreased 0 0 5
Patients who reported pain at T0 had their hope score 
decreased at the end of treatment. This decrease was statisti-
cally significant (p = 0.034). Univariate analysis characterizes 
this variable as a factor associated to hope.
The variables that presented statistical significance in the 
univariate analysis were used to adjust the logistic regression 
model. This model characterized the multivariate statistics, 
allowing for identifying predictors of hope.
Pain was the only tested variable predictive of hope in 
the sample studied.
Multivariate analysis using the odds ratio identifies 
pain as a predictor of decreased hope. If the patient reports 
pain, the chance of the HHI score decreasing is 2.199 
times greater than in a patient who does not report pain 
(p = 0.042).
The variables religiosity, fatigue and coping did not pres-
ent significant alterations with variation of the hope score.
DISCUSSION
This longitudinal study investigated hope and its predic-
tive factors in 122 breast cancer patients undergoing che-
motherapy at the beginning and at the end of treatment.
Patients in this study had a median HHI score of 43 
at T0 and 45 at T1, which represents a high level of hope 
since the score ranges from 12 to 48. Results similar to the 
present study were found in the HHI validation study for 
the Portuguese language, in which a mean score of 41.57 
was found for cancer patients, 40.46 for diabetic patients 
and 40.88 for the companions of these patients(5).
Chinese women with breast cancer undergoing chemo-
therapy had a high hope score, with a total score of 38.62 ± 
4.56. There was no statistical difference between hope and 
age, educational level, marital status, work condition or can-
cer stage, however there was statistical difference between 
hope and monthly income; the higher the monthly income, 
the greater the hope(22).
Another study which aimed to describe hope in onco-
logic patients with pain (n = 225), and to determine which 
variables were related to hope, concluded that hospitalized 
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cancer patients with pain had higher hope than the popula-
tion of Norway. However, the patients reported lower scores 
for the item “I’m afraid of my future” on the HHI(23).
A Japanese study comparing the symptoms of suffering 
and reaching a good death among older adult and young 
patients with cancer identified the loss of hope and pleasure 
in older adult patients with metastatic cancer(24).
The time interval between the perception of breast cancer 
symptoms and the beginning of treatment had a median 
of 8 months; this is a long period considering the need to 
establish treatment as early as possible. This time interval was 
a factor associated to hope in this study. Patients who took 
longer to start chemotherapy treatment had a significant 
decrease in their hope scores throughout the treatment. A 
Brazilian study showed that the longest delay in the conduct 
of breast cancer cases occurred between the mammography 
and biopsy of suspicious lesions. The greatest delay in diag-
nosis was related to more advanced stages of the disease. 
The interval between a suspicious mammography and the 
onset of systemic therapy (> 180 days) stands out, since this 
is the time interval in which potential micrometastases can 
take place, leading the disease to become metastatic and 
generally incurable(25).
The patients in this study presented an increase in the 
Karnofsky Performance Status at the end of treatment 
when compared to the beginning. The median KPS in these 
patients was 90 at T0 and T1, which means that the patients 
were able to lead a normal life even when dealing with minor 
signs or symptoms of the disease. KPS was found to be a 
factor associated to hope in this study. The median of 90 is a 
high value of KPS when compared to that of cancer patients 
with pain from a Norwegian study, which obtained an aver-
age of 64.9% (± 15.6)(23).
Anxiety and depression have been identified as com-
mon psychological distress factors in most cancer patients(10). 
The group that had decreased hope presented an increase 
in the depression score, which favors evaluating hope as a 
positive way in coping with the disease(1). Depression in 
this sample was a factor associated to hope. An American 
study investigating hope and suffering symptoms found 
that depression was the only inversely significant variable 
in the multivariate analysis. The other variables (pain, activ-
ity, nausea, depression, feeling sad, feeling nervous, anxiety, 
drowsiness, appetite, well-being and dyspnea) had a weak 
correlation with hope(11).
The patients in this study showed increased self-esteem 
at the end of the chemotherapy treatment. In cancer patients, 
self-esteem showed a positive correlation with hope, mean-
ing that the higher the self-esteem score, the higher the hope 
score(5). Statistical analysis revealed self-esteem as a factor 
associated to hope.
Breast pain was present in 54 patients at the start of 
treatment, making up 44% of the sample. At the end of 
the treatment, 47 patients (38.5%) complained of pain. This 
information is similar to a study conducted to investigate the 
prevalence and comorbidity of pain and fatigue in women 
with breast cancer in which 47% of the patients presented 
pain(26). Pain imposes many limits on the lifestyle of the 
patient who suffers from it. Immobility and impatience are 
some of the outcomes of disease progression. The concept 
of total pain consisting of the physical, mental, social, and 
spiritual components reveals that pain relief is not achieved 
if all of these areas are neglected. Sensitive, emotional and 
cultural aspects are inseparable in pain and should also 
be evaluated(26).
The main result of this study narrowed the concepts of 
pain and hope. In this sample, pain was an associated factor 
and the only predictor of hope. This is noticeable in clinical 
practice; however, there is a need for more research that 
investigates the topic. New studies can be carried out with 
different samples.
For nursing, this result represents collaboration in 
improving care for cancer patients with pain. A disorder 
caused by pain requires interdisciplinary assistance, in addi-
tion to evaluation, pharmacological and non-pharmacolog-
ical therapy. Longitudinal studies with interventions that 
increase hope and involve its associated factors and predic-
tors constitute a vast field to be explored in future research.
This study had the decrease in the number of patients 
from T0 to T1 as a limitation. This loss occurred due to 
metastatic disease reported in the medical records after start-
ing treatment. There were also changes in dates in scheduling 
patients (without previous information), and deaths reported 
by relatives via telephone call.
CONCLUSION
The results of this study allow us to conclude that the 
hope in women with breast cancer undergoing chemo-
therapy treatment who composed the sample were posi-
tively evaluated at the beginning of the chemotherapy and 
improved significantly at the end of it.
Patients who reported pain at the start of treatment had 
a decreased hope score at the end of treatment (p = 0.034). 
Among the analyzed variables, pain was the only predictor 
of hope. The presence of pain may decrease hope by 2.199 
times more than in patients who do not report having pain.
This study significantly contributes to the knowledge 
for clinical practice of cancer patients, since it presents 
unprecedented results that allow us to understand the fac-
tors associated to hope, as well as its predictive factor and 
to implement improvement in the care of these patients.
RESUMO
Objetivo: Identificar os fatores preditores da esperança nas pacientes com câncer de mama em tratamento quimioterápico. Método: 
Estudo prospectivo longitudinal. A amostra foi de 122 mulheres que responderam aos instrumentos de esperança, ansiedade e 
depressão, coping, fadiga, religiosidade e autoestima no primeiro e no último ciclo de quimioterapia. Essas variáveis foram utilizadas no 
ajuste do modelo de regressão logística que caracterizou a estatística multivariada permitindo a identificação das variáveis preditoras. 
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Resultado: O aumento da esperança ao final do tratamento quimioterápico foi estatisticamente significante (p = 0,012). A demora na 
realização do tratamento desde o início dos sintomas do câncer de mama, o Karnofsky Performance Status, a depressão, a autoestima e a 
dor foram caracterizadas como fatores associados à esperança pela análise univariada. Dentre as variáveis analisadas, a dor apresentou-
se como o único fator preditor da esperança. Conclusão: A dor foi o fator preditor nesta amostra. A esperança aumentou durante o 
tratamento e revelou os fatores associados: Karnofsky Performance Status, demora no início do tratamento, depressão, autoestima e dor. 
Este estudo trouxe uma contribuição multidisciplinar, permitiu compreender os fatores que podem influenciar a esperança e apresentou 
subsídios à assistência de enfermagem. Os dados evidenciaram condições de melhora ou agravamento da esperança, o que requer 
atenção interdisciplinar em Oncologia.
DESCRITORES
Neoplasias da Mama; Quimioterapia; Esperança; Dor; Enfermagem Oncológica; Reprodutibilidade dos Testes.
RESUMEN
Objetivo: identificar los factores predictivos de la esperanza en las pacientes con cáncer de mama en tratamiento quimioterápico. 
Método: Estudio prospectivo longitudinal. La muestra fue de 122 mujeres que respondieron a los instrumentos de esperanza, ansiedad y 
depresión, coping (enfrentamiento), fatiga, religiosidad y autoestima el primero y el último ciclo de quimioterapia. Dichas variables fueron 
utilizadas en el ajuste del modelo de regresión logística que caracterizó la estadística multivariada permitiendo la identificación de las 
variables predictivas. Resultado: El aumento de la esperanza al final del tratamiento quimioterápico fue estadísticamente significativo 
(p = 0,012). La demora en la realización del tratamiento desde el inicio de los síntomas del cáncer de mama o Karnofsky Performance 
Status, la depresión, la autoestima y el dolor se caracterizaron como factores asociados con la esperanza por el análisis univariado. Entre 
las variables analizadas, el dolor se presentó como el único factor predictor de la esperanza. Conclusión: El dolor fue el factor predictor 
en esta muestra. La esperanza aumentó durante el tratamiento y reveló los factores asociados: Karnofsky Performance Status, demora en el 
inicio del tratamiento, depresión, autoestima y dolor. Este estudio brindó un aporte multidisciplinario, permitió comprender los factores 
que pueden influenciar la esperanza y presentó subsidios para la asistencia de enfermería. Los datos evidenciaron condiciones de mejora 
o agravamiento de la esperanza, lo que requiere atención interdisciplinaria en Oncología.
DESCRIPTORES
Neoplasias de la Mama; Quimioterapia; Esperanza; Dolor; Enfermería Oncológica; Reproducibilidad de Resultados.
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